Wang Hongqin

Wang Hongqin


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019 in Anti-Cancer Drugs
Verified
Journal Article
Open access
WHWang Hongqin
Wang Hongqin
SRShuxian Ren
Shuxian Ren
YXYongming Xu
Yongming Xu
WMWang Miao
Wang Miao
XHXintao Huang
Xintao Huang
PKPengzhou Kong
Pengzhou Kong
A double-strand breaks in the G1 and S phases. However, endogenous or acquired resistance to TMZ limits glioma patients’ clinical outcome and is also an important cause of glioma replase. MicroRNA-195 (miR-195) plays an important role in the regulation of G1-phase/S-phase transition, DNA damage repair, and apoptosis of tumor cells. We found that miR-195 expression was significantly decreased in TMZ-resistant glioma cells induced with TMZ and correlated to the resistance index negatively. Also, the exogenous expression of miR-195 reversed TMZ resistance and induced the apoptosis of TMZ-resistant glioblastoma cells. Further bioinformatics analysis showed cyclin E1 (CCNE1) was a potential target gene of miR-195. Knockdown of CCNE1 partially reversed the effect of decreased miR-195 on TMZ resistance. The data from The Cancer Genome Atlas – Cancer Genome further suggested that hsa-miR-195 could negatively regulate the expression of CCNE1 in glioma. In conclusion, miR-195 reverses the resistance to TMZ by targeting CCNE1 in glioma cells and it could act as a potential target for treatment in glioma with TMZ resistance....

12 January 2023 in Frontiers in Genetics
Verified
Journal Article
Open access
YNYijie Ning
Yijie Ning
YLYufei Li
Yufei Li
WHWang Hongqin
Wang Hongqin
Background: Annexin A2 (ANXA2) belongs to the Annexin A family and plays a role in epithelial-mesenchymal transition, fibrinolysis, and other physiological processes. Annexin A2 has been extensively implicated in tumorigenesis and development in previous studies, but its precise role in pan-cancer remains largely unknown.Methods: We adopted bioinformatics methods to explore the oncogenic role of Annexin A2 using different databases, including the Cancer Genome Atlas (TCGA), the Genotype-Tissue Expression (GTEx) biobank, the Human Protein Atlas (HPA), the Gene Expression Profiling Interaction Analysis (GEPIA) and cBioPortal. We analyzed the differential expression of Annexin A2 in different tumors and its relationship with cancer prognosis, immune cell infiltration, DNA methylation, tumor mutation burden (TMB), microsatellite instability (MSI) and mismatch repair (MMR). Furtherly, we conducted a Gene Set Enrichment Analysis (GSEA) to identify the Annexin A2-related pathways.Results: Annexin A2 expression was upregulated in most cancers, except in kidney chromophobe (KICH) and prostate adenocarcinoma (PRAD). Annexin A2 showed a good diagnostic efficacy in twelve types of cancer. The high expression of Annexin A2 was significantly associated with a reduced overall survival, disease-specific survival and progression-free interval in seven cancers. The Annexin A2 expression was variably associated with infiltration of 24 types of immune cells in 32 tumor microenvironments. In addition, Annexin A2 expression was differently associated with 47 immune checkpoints, immunoregulators, DNA methylation, tumor mutation burden, microsatellite instability and mismatch repair in pan-cancer. Gene Set Enrichment Analysis revealed that Annexin A2 was significantly correlated with immune-related pathways in fifteen cancers.Conclusion: Annexin A2 widely correlates with immune infiltration and may function as a promising prognostic biomarker in many tumors, showing its potential as a target for immunotherapy in pan-cancer.

23 September 2025 in Colloids and Surfaces B: Biointerfaces
Verified
Journal Article
Closed access
TGTao Gong
Tao Gong
RFRuolan Feng
Ruolan Feng
HZHuirui Zhu
Huirui Zhu
MZMoxuan Zhao
Moxuan Zhao
BYBaofeng Yu
Baofeng Yu
RGRui Guo
Rui Guo

16 March 2024 in Neurosurgical Review
Verified
Journal Article
Closed access
PDF file
WCWen-Qiang Che
Wen-Qiang Che
YWYu-Jiao Wang
Yu-Jiao Wang
LYLiu Yang
Liu Yang
WHWang Hongqin
Wang Hongqin
XWXiangyu Wang
Xiangyu Wang
JLJun Lyu
Jun Lyu

15 May 2025 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
ZQZhizhao Qu
Zhizhao Qu
JZJiajia Zhao
Jiajia Zhao
LYLiu Yang
Liu Yang
YFYuanwei Fu
Yuanwei Fu
RBRui Bai
Rui Bai
WHWang Hongqin
Wang Hongqin
Objective: Alkylating agents and bevacizumab are both first-line chemotherapeutic options for the treatment of glioblastoma; however, their mechanisms of action differ substantially. This study aimed to compare the safety profiles of these two drug classes in the treatment of glioblastoma to inform clinical decision-making.Methods: Adverse events reported between the first quarter of 2004 and the fourth quarter of 2023 were analyzed using data from the FDA Adverse Event Reporting System (FAERS) database. Disproportionality analysis was employed to assess and compare the AE signals associated with bevacizumab and alkylating agents.Results: In the context of glioblastoma treatment, 3,323 adverse reports were associated with bevacizumab, 5,283 with temozolomide, and 427 with lomustine. The most frequently reported AEs for bevacizumab were fatigue (n = 276), hypertension (n = 220), and headache (n = 199). Compared to temozolomide, bevacizumab was more strongly associated with “vascular disorders,” “renal and urinary disorders,” and “hypertension.” Notably, bevacizumab appeared to offer a potential safety advantage with respect to hematological adverse events.Conclusion: Our analysis indicates that bevacizumab exhibits a distinct safety profile compared to alkylating agents, particularly demonstrating a lower incidence of hematological adverse events. Further prospective studies are warranted to validate these findings and to elucidate the underlying mechanisms responsible for the observed adverse events.

31 October 2025 in Frontiers in Endocrinology
Verified
Journal Article
Open access
PDF file
JZJiawei Zhang
Jiawei Zhang
YHYurui He
Yurui He
YNYijie Ning
Yijie Ning
RBRui Bai
Rui Bai
WHWang Hongqin
Wang Hongqin
Objective: To identify risk factors for cerebrospinal fluid (CSF) leakage after endoscopic endonasal pituitary adenoma surgery and to develop a clinical prediction model aimed at facilitating early detection and reducing the risk of related complications. Methods: Clinical data were retrospectively collected from patients who underwent endoscopic endonasal pituitary adenoma resection between January 2021 and September 2024. Postoperative CSF leakage was diagnosed based on clinical manifestations, glucose testing, and expert consensus. Univariable and multivariable logistic regression analyses were performed to determine independent risk factors, which were subsequently incorporated into a nomogram. The predictive performance of the model was evaluated using receiver operating characteristic (ROC) curves, calibration curves, and decision curve analysis (DCA). Results: Among 254 patients, 19 (7.48%) developed postoperative CSF leakage. Compared with those without leakage, affected patients exhibited larger tumor diameters, wider sellar floor bony windows, higher intraoperative CSF leak grades, greater suprasellar extension, and higher postoperative pneumocephalus grades. Multivariate logistic regression identified postoperative pneumocephalus grade (OR = 12.90, 95% CI: 3.24-59.80, p < 0.001), sellar floor bony window size (OR = 1.20, 95% CI: 1.07-1.37, p = 0.004), suprasellar extension grade (OR = 5.87, 95% CI: 1.15-46.10, p = 0.049), and intraoperative CSF leak grade (OR = 4.71, 95% CI: 1.14-20.30, p = 0.032) as independent predictors of postoperative CSF leakage. The nomogram incorporating these factors achieved excellent predictive accuracy, with an AUC of 0.948 (95% CI: 0.906–0.991). Conclusion: This study confirms that a higher grade of pneumocephalus and a larger sellar floor bony window are significant risk factors for postoperative CSF leak following endoscopic endonasal transsphenoidal surgery for pituitary tumors. Building on these findings, we developed a clinical prediction model for postoperative CSF leak by integrating relevant preoperative, intraoperative, and postoperative factors. This model facilitates the early prevention, identification, and management of CSF leaks, which is crucial for reducing the risk of associated complications and improving patient outcomes.